Annual Report

Overview

The report highlights clinical pipeline progress: Masupirdine's Phase 3 enrolment exceeded 95%, Ropanicant completed Phase 2b, and Samelisant entered Phase 3. Consolidated R&D expenditure was ₹24,818.81 Lakhs in FY2025-26. The BRSR also sets a 2027 goal for all employees to have access to professional-development opportunities.

Document

Report type: Annual Report with Sustainability Disclosures
Class: Embedded
Scope: Full report
Fiscal year: 2025-2026
Period: 1 April 2025 – 31 March 2026
Publication date: 13 May 2026
Language: English
Pages
File size
Restatement: Disclosed

Standards

Other

Materiality

Assessment
Basis

Assurance

Statement included

Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services